TY - JOUR T1 - Vitamin D – contrary to vitamin K – does not associate with clinical outcome in hospitalized COVID-19 patients JF - medRxiv DO - 10.1101/2020.11.07.20227512 SP - 2020.11.07.20227512 AU - Jona Walk AU - Anton S.M. Dofferhoff AU - Jody M.W. van den Ouweland AU - Henny van Daal AU - Rob Janssen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/09/2020.11.07.20227512.abstract N2 - SARS-CoV-2 causes remarkably variable disease from asymptomatic individuals to respiratory insufficiency and coagulopathy. Vitamin K deficiency was recently found to associate with clinical outcome in a cohort of COVID-19 patients. Vitamin D has been hypothesized to reduce disease susceptibility by modulating inflammation, yet little is known about its role in disease severity. Considering the critical interaction between vitamin K and vitamin D in calcium and elastic fiber metabolism, we determined vitamin D status in the same cohort of 135 hospitalized COVID-19 patients by measuring blood 25(OH)D levels. We found no difference in vitamin D status between those with good and poor outcome (defined as intubation and/or death). Instead, we found vitamin D sufficient persons (25(OH)D >50 nmol/L) had accelerated elastic fiber degradation compared to those with mild deficiency (25(OH)D 25-50 nmol/L). Based on these findings, we hypothesize that vitamin D might have both favorable anti-inflammatory and unfavorable pro-calcification effects during COVID-19 and that vitamin K might compensate for the latter.Competing Interest StatementRJ discloses application of a patent on vitamin K in COVID-19. RJ, JW and ASMD have a scientific collaboration with Kappa Bioscience AS, a manufacturer of vitamin K2 (MK-7). JMWO and RJ are owners of Desmosine.com. HD declares no competing interests.Funding StatementNot applicable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CMO Arnhem-NijmegenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request. ER -